血清外泌体 miR-451a 可作为胰腺癌的候选标志物。
Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer.
机构信息
Department of Laboratory Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Co-first author.
出版信息
Int J Biol Markers. 2022 Mar;37(1):74-80. doi: 10.1177/17246008211070018. Epub 2022 Jan 10.
OBJECTIVES
The aim of this study was to explore the diagnostic efficiency of serum exosomal miR-451a as a novel biomarker for pancreatic cancer.
METHODS
Serum samples were collected prior to treatment. First, we analyzed microRNA (miRNA) profiles in serum exosomes from eight pancreatic cancer patients and eight healthy volunteers. We then validated the usefulness of the selected exosomal miRNAs as biomarkers in another 191 pancreatic cancer patients, 95 pancreatic benign disease (PB) patients, and 90 healthy controls.
RESULTS
The expression of miR-451a in serum-derived exosomes from pancreatic cancer patients was significantly upregulated compared with those from PB patients and healthy individuals. Serum exosomal miR-451a showed excellent diagnostic power in identifying pancreatic cancer patients. In addition, exosomal miR-451a showed a significant association with clinical stage and distant metastasis in pancreatic cancer, and the expression level of serum exosomal miR-451a was sensitive to therapy and relapse.
CONCLUSIONS
Serum exosomal miR-451a might serve as a novel diagnostic marker for pancreatic cancer.
目的
本研究旨在探讨血清外泌体 miR-451a 作为一种新型胰腺癌诊断标志物的诊断效率。
方法
治疗前采集血清样本。首先，我们分析了 8 例胰腺癌患者和 8 例健康志愿者血清外泌体中的 microRNA（miRNA）谱。然后，我们在另外 191 例胰腺癌患者、95 例胰腺良性疾病（PB）患者和 90 例健康对照者中验证了所选外泌体 miRNA 作为生物标志物的有用性。
结果
与 PB 患者和健康个体相比，胰腺癌患者血清来源的外泌体中 miR-451a 的表达明显上调。血清外泌体 miR-451a 在识别胰腺癌患者方面具有优异的诊断能力。此外，外泌体 miR-451a 与胰腺癌的临床分期和远处转移有显著关联，血清外泌体 miR-451a 的表达水平对治疗和复发敏感。
结论
血清外泌体 miR-451a 可能作为一种新型的胰腺癌诊断标志物。
Zotero 插件